Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole vs Tamoxifen in Neoadjuvant ER+ Breast Cancer
NCT00949598Phase 3Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Dec 2008
- Primary completion
- Oct 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of letrozole in breast cancer (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Changes in Ki67 and PCNA expression at 4 months. Started Dec 2008; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00949598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00949598.